Notes

Glucagon-like peptide A single decreases lipotoxicity throughout non-alcoholic steatohepatitis.
is investigation may help in understanding these tumor pathology at molecular level.
These tumors did not have any insertion/ deletion mutations, nonsense, or truncated mutations in it. The screening of PKHD1 gene revealed signature mutations for the solid tumors studied by NGS method. This investigation may help in understanding these tumor pathology at molecular level.
Breast cancer represents the second most frequent cause of brain metastases after lung cancer. Previous studies have identified the subgroups of patients with triple-negative and HER2-positive as having an increased risk for the development of brain metastases. We are not aware in Kurdistan - Iraq of any national studies that are in parallel with these findings.

A cross-sectional descriptive study conducted on 57 patients who were known cases of breast cancer with brain metastasis, managed with whole brain radiotherapy at a tertiary radiotherapy institute in two years (January 2015 to December 2016), as a convenient sample. Data were collected from patients' archives and phone calls and then analyzed using SPSS version 23.

Younger age at diagnosis and cancers with HER2-positive receptor phenotype are risk factors for brain metastasis. Median survival post-brain metastasis is significantly affected by receptor phenotypes (2 months in triple negative versus 7 months in hormone receptor positive) and performance status (18 months if performance score of 70% and above versus 1.5 months if it is 60% and less).

Primary breast cancer patients have more risk to develop brain metastases if they are at younger age and HER2-positive and the survival post-brain metastases is dramatically affected by both triple negative receptor phenotype and lower performance score.
Primary breast cancer patients have more risk to develop brain metastases if they are at younger age and HER2-positive and the survival post-brain metastases is dramatically affected by both triple negative receptor phenotype and lower performance score.
Oncotype DX is approved in multiple countries but its cost-effectiveness is a matter of considerable health debate. Lebanon is high-middle income country according to the World Bank classification however it is facing a mounting financial and health care burden from cancer. Therefore, we conducted a costeffectiveness analysis of Oncotype DX based Lebanese on real-life data.

We updated a Canadian cost-effectiveness model of Oncotype DX by incorporating Lebanese data. The patient population was a real-life cohort of 82 women diagnosed with hormone receptor - positive and HER2 - negative early breast cancer.

Overall, providing Oncotype DX to only intermediate Adjuvant! Online risk patients costs an additional $83 CAD (93,883 LBP) per additional QALY. From this point, extending provision to also cover high Adjuvant! Online risk patients costs an additional $736 CAD (831,578 LBP) per additional QALY. From this point, extending provision further to also cover low Adjuvant! Online risk patients (such that Onco makers regarding the cost-effectiveness of providing Oncotype DX to Lebanese patients.
Oral squamous cell carcinoma (OSCC) is an aggressive epithelial malignancy. Diagnosis at an early stage is a key for successful cancer therapy. Development of sensitive, specific, and non-invasive tumor markers, especially, in serum, is needed. Midkine (MK) is a plasma-secreted multifunctional peptide which is a heparin-binding growth factor.

Blood samples were collected from 20 patients with OSCC, 20 patients with oral premalignancy and 10 healthy controls. Only histologically proven oral cancer and precancerous patients were taken as test subjects. Healthy individuals without predisposing habits were selected. The Human Midkine ELISA kit (Biovendor,Czech Republic) was stored at 2-80C.

One way ANOVA was applied using SPSS software.

Midkine Concentration in Poorly differentiated was significantly higher than Well differentiated OSCC. Midkine Concentration in stage II was significantly higher than stage I. There was a very strong positive and significant correlation between severity of disease and Midkal. Serum MK concentration may serve for cancer screening and monitoring the prognosis of the disease.
The The study proposed to assess the relation between the body mass index (BMI) and clinicopathological features of metastatic urinary bladder cancer (uBCa) and the influence on survival outcome.

A retrospective study included 201 metastatic uBCa patients. They classified into three groups according to BMI, group I; a BMI of 18.5-24.9 kg/m2, group II; a BMI of 25-29.9 kg/m2, and group III; BMI ≥ 30 kg/m2. The Kaplan - Meier curve used for survival analysis.

69 patients (34.3%) belonged to group I, 75 patients (37.3%) belonged to group II, and 57 patients (28.4%) belonged to group III. Smoking history was detected in 44.8% of patients with Performance Status (PS) 0 in 55.2%, and PS 1 in 26.9%. Of note, 44.8% of patients responded to 1st chemotherapy and 50.7% received more than 2 lines. Through the univariate analysis, poor prognostic outcome was associated with male (P= 0.01), smoking (P=0.002), BMI group II and group III (p=0.00), PS 2 compared with PS 0 (P&lt;0.001), metastasis to liver, lung, and lymph node (P&lt;0.001), and no response to first line chemotherapy (P&lt;0.001). While no effect for age (P=0.1), bone metastasis (P=0.6), serum LDH (P=0.1), serum albumin (P=0.4), and ≥2 chemotherapy lines (P=0.5) on survival outcome. After the follows-up period, the OS was 12.7 months for all patients. Regarding the BMI groups, the median OS was 23.5 months, 12.9 months, and 10.2 months for group I, group II, and group III respectively (p<0.001).

High BMI associated with aggressive clinico-pathological features and poor survival outcome in metastatic uBCa.
High BMI associated with aggressive clinico-pathological features and poor survival outcome in metastatic uBCa.
Lung cancer is the most deadly and sumptuous cancer across the globe. Cancer occurrence is increasing progressively and there is no ideal cure yet. Therefore, new therapeutic areas are needed. AMI-1 price The use of herbal extracts due to its properties such as antioxidant activity, anti-proliferative effect, and few side effects can be promising in the treatment of cancer. This study aimed to compare the effect of Echinophora platyloba DC. and Cordia myxa L extracts on apoptosis induction in A549 cancer cells.

In this experiment, the A549 cell line was first cultured in DMEM medium containing 10% FBS and then treated with different concentrations of both compounds. MTT assay was performed to determine IC50 and to compare the viability of cells treated with different concentrations of Echinophora platyloba DC. and Cordia myxa L seed on days 1, 3 and 5. QRT-PCR test was used to investigate the effects of Echinophora platyloba DC. and Cordia myxa L with IC50 on apoptosis induction.

MTT results showed that both plant extracts resulted in cell death and decreased viability of lung cancer cells.
Homepage: https://www.selleckchem.com/products/ami-1.html